Skip to main content

Drug Interactions between capecitabine and sorafenib

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

capecitabine SORAfenib

Applies to: capecitabine and sorafenib

MONITOR: Coadministration with sorafenib may increase the plasma concentrations of capecitabine and its active metabolite, 5-fluorouracil (5-FU). The mechanism of interaction has not been described. According to the sorafenib labeling, concomitant use of capecitabine (750 to 1050 mg/m2 twice daily on days 1 to 14 every 21 days) with sorafenib (200 or 400 mg twice daily continuously) increased capecitabine exposure by 15% to 50% and 5-FU exposure by 0% to 52%. The clinical significance of these modest changes is unknown. Sorafenib pharmacokinetics were not significantly altered by capecitabine.

MANAGEMENT: Caution may be advisable when capecitabine is used with sorafenib. Patients should be monitored closely for potential toxicities of capecitabine such as diarrhea, hand and foot syndrome, hyperbilirubinemia, myelosuppression and cardiotoxicity, and the dosage adjusted accordingly.

References (2)
  1. (2005) "Product Information. Nexavar (sorafenib)." Bayer Pharmaceutical Inc
  2. Cerner Multum, Inc. "UK Summary of Product Characteristics."

Drug and food interactions

Moderate

SORAfenib food

Applies to: sorafenib

ADJUST DOSING INTERVAL: Food may reduce the oral absorption and bioavailability of sorafenib. According to the product labeling, sorafenib bioavailability was reduced by 29% when administered with a high-fat meal compared to administration in the fasted state. When given with a moderate-fat meal, bioavailability was similar to that in the fasted state.

MANAGEMENT: To ensure maximal and consistent oral absorption, sorafenib should be taken at least one hour before or two hours after eating.

References (1)
  1. (2005) "Product Information. Nexavar (sorafenib)." Bayer Pharmaceutical Inc

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer